Table 1.
Characteristics of Hodgkin lymphoma (HL) patients who subsequently developed pancreatic cancer (cases) and matched controls
| Cases (n = 36) |
Controls (n = 70) |
|||
|---|---|---|---|---|
| N | (%) | N | (%) | |
| Study center (years included) | ||||
| Denmark (1943–1999) | 3 | (8.3) | 4 | (5.7) |
| Finland (1953–2002) | 9 | (25.0) | 18 | (25.7) |
| Iowa, USA (1973–2001) | 1 | (2.8) | 2 | (2.9) |
| The Netherlands (1965–2002) | 3 | (8.3) | 6 | (8.6) |
| Norway (1953–2000) | 4 | (11.1) | 8 | (11.4) |
| Ontario, Canada (1964–2003) | 6 | (16.7) | 12 | (17.1) |
| Sweden (1958–2002) | 10 | (27.8) | 20 | (28.6) |
| Sex | ||||
| Male | 21 | (58.3) | 41 | (58.6) |
| Female | 15 | (41.7) | 29 | (41.4) |
| Year of HL diagnosis | ||||
| 1963–1969 | 10 | (27.8) | 19 | (27.1) |
| 1970–1974 | 12 | (33.3) | 24 | (34.3) |
| 1975–1979 | 8 | (22.2) | 13 | (18.6) |
| 1980–1989 | 6 | (16.7) | 14 | (20.0) |
| Age at diagnosis of HL (years) | ||||
| 12–29 | 9 | (25.0) | 18 | (25.7) |
| 30–49 | 10 | (27.8) | 22 | (31.4) |
| 50–59 | 10 | (27.8) | 17 | (24.3) |
| 60–76 | 7 | (19.4) | 13 | (18.6) |
| HL histology | ||||
| Nodular sclerosis | 7 | (19.4) | 19 | (27.1) |
| Mixed cellularity | 10 | (27.8) | 20 | (28.6) |
| Lymphocyte predominant | 5 | (13.9) | 8 | (11.4) |
| Lymphocyte depleted | 3 | (8.3) | 6 | (8.6) |
| Unspecifieda | 11 | (30.6) | 17 | (24.3) |
| HL stage | ||||
| I | 13 | (36.1) | 22 | (31.4) |
| II | 13 | (36.1) | 29 | (41.4) |
| III | 7 | (19.4) | 11 | (15.7) |
| IV | 3 | (8.3) | 8 | (11.4) |
| HL relapse during follow-up | ||||
| No | 17 | (47.2) | 48 | (68.6) |
| Yes | 19 | (52.8) | 22 | (31.4) |
| HL treatment summaryb | ||||
| RT and AA | 22 | 25 | ||
| Initial therapy only | 4 | (11.1) | 13 | (18.6) |
| Initial and subsequent therapy | 18 | (50.0) | 12 | (17.1) |
| RT (no AA) | 10 | 33 | ||
| Initial therapy only | 9 | (25.0) | 26 | (37.1) |
| Any subsequent therapy | 1 | (2.8) | 7 | (10.0) |
| AA (no RT) | 3 | 11 | ||
| Initial therapy only | 3 | (8.3) | 8 | (11.4) |
| Any subsequent therapy | 0 | (0.0) | 3 | (4.3) |
| RT (initial), unknown AA | 1 | (2.8) | 0 | (0.0) |
| No RT, unknown AA | 0 | (0.0) | 1 | (1.4) |
| Interval from HL to pancreatic cancer (matched time period for controls) (years) | ||||
| 5–14 | 16 | (44.4) | 31 | (44.3) |
| 15–24 | 14 | (38.9) | 29 | (41.4) |
| 25–33 | 6 | (16.7) | 10 | (14.3) |
| Age at pancreatic cancer diagnosis (years) | ||||
| 36–49 | 6 | (16.7) | – | |
| 50–69 | 18 | (50.0) | – | |
| 70–87 | 12 | (33.3) | – | |
| Stage of pancreatic cancer | ||||
| I/II | 9 | (25.0) | – | |
| III | 7 | (19.4) | – | |
| IV | 15 | (41.7) | – | |
| Not otherwise specified | 5 | (13.9) | – | |
aIncludes Hodgkin granuloma (eight cases, eight controls) and unspecified histology (three cases, nine controls).
bTreatment summary includes all therapy received (initial and subsequent). Initial treatment was defined from the start of treatment until the occurrence of a >3-month period without treatment. Subsequent therapy may have been given during the same treatment course, sequentially, or separately if a patient had multiple recurrences.
AA, alkylating agent-containing chemotherapy; N, number; RT, radiotherapy.